Rigel Pharmaceuticals Inc. is a biotechnology company dedicated to discovering, developing, and commercializing innovative therapies, primarily for cancer and hematologic disorders. Its scientific approach centers on targeting key signaling pathways that drive disease biology, enabling the development of more precise treatments for patients with serious, often hard-to-treat conditions.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Rigel’s research and development initiatives focus on developing its interleukin receptor-associated kinases 1 and 4. The company is developing an extensive patent portfolio in the US, Europe, Japan, and other major market countries to protect its commercial and clinical programs. The company is involved in clinical trials for investigational candidates like R289 for Lower-risk Myelodysplastic Syndromes and is developing RIPK1 inhibitors for autoimmune, inflammatory, and neurodegenerative disorders in collaboration with Eli Lilly. It is also exploring the use of its marketed products, such as olutasidenib, pralsetinib, and fostamatinib, in various therapeutic areas and combination therapies. As of December 2025, the company owned 43 issued US patents for fostamatinib, 20 issued US patents for olutasidenib, six issued US patents for pralsetinib, and four issued US patents for R289. The company is involved in multiple pipeline products, including TAVALISSE (fostamatinib), REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), and R289. Major technology alliances include a partnership with Eli Lilly for the development of RIPK1 inhibitors. In FY2025, the company spent US$33.3 million on its R&D activities, which, as a percentage of revenue, stood at 11.3%.